The steep drop in Valeant Pharmaceuticals International Inc.’s stock in recent months hurt a lot of investors, with a surprising exception: the two biggest mutual funds that specialize in health care.

The $51 billion Vanguard Health Care Fund and the $15 billion Fidelity Select Biotechnology Portfolio haven’t invested in the drugmaker at least since 2011, even though Valeant’s shares were on a tear before their recent dive.

...